BridgeMD
New treatment option for Trace Element Deficiency
Official title Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers
ClinicalTrials.gov ID: NCT06060990
What this study is testing
- What it's testing
- The aim of the study is to determine the total concentration of selected trace elements (Cu, Zn, Fe), the proportion of free Cu and Cu bound to ceruloplasmin and the isotopic ratio of Cu65/Cu63 in blood serum samples from healthy volunteers and cancer patients using inductively coupled plasma mass spectrometry-based methods. The results will be statistically evaluated and the potential applications of the analytical methods used in cancer diagnosis and therapy will be assessed.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80. Healthy volunteers may be eligible.
You may be able to join if
- aged ≥18 years
- cytologically or histologically verified biliary tract cancer
- no prior systemic therapy and no radiation therapy for advanced, inoperable or metastatic disease
- WHO performance status 0 - 2 (ECOG criteria)
- imaging diagnosis (CT of thoracic and abdominal organs) performed within 4 weeks prior to the first administration of systemic therapy
You likely can't join if
- prior systemic treatment and radiation therapy for inoperable, metastatic disease
- WHO performance status \> 2 (ECOG criteria)
- contraindications to immunotherapy (known immunodeficiency or active immunosuppressive therapy or active autoimmune disease requiring treatment)
- other malignancies, except cured basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or other cured solid tumours...
See the full eligibility criteria
- aged ≥18 years
- cytologically or histologically verified biliary tract cancer
- no prior systemic therapy and no radiation therapy for advanced, inoperable or metastatic disease
- WHO performance status 0 - 2 (ECOG criteria)
- imaging diagnosis (CT of thoracic and abdominal organs) performed within 4 weeks prior to the first administration of systemic therapy
- disease measurable by RECIST or ECOG criteria
- signed Consent to Participate in Clinical Research form
- prior systemic treatment and radiation therapy for inoperable, metastatic disease
- WHO performance status \> 2 (ECOG criteria)
- contraindications to immunotherapy (known immunodeficiency or active immunosuppressive therapy or active autoimmune disease requiring treatment)
- other malignancies, except cured basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or other cured solid tumours without recurrence ≥ 3 years after treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Ljubljana, Slovenia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ljubljana, Slovenia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.